<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010093434">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Petit, E.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Cortaredona, Sébastien</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Sicco, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Ranque, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Menu, E.</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Combined immunoCAP and western blot for the diagnosis of Aspergillus lung disease</title>
        <secondary-title>Mycoses</secondary-title>
      </titles>
      <pages>e70058 [9 p.]</pages>
      <keywords>
        <keyword>ABPA</keyword>
        <keyword>aspergillus lung disease</keyword>
        <keyword>aspergillus sensitisation</keyword>
        <keyword>CPA</keyword>
        <keyword>diagnostic tests</keyword>
        <keyword>pulmonary aspergillosis</keyword>
        <keyword>serology</keyword>
        <keyword>FRANCE</keyword>
      </keywords>
      <dates>
        <year>2025</year>
      </dates>
      <call-num>fdi:010093434</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Mycoses</full-title>
      </periodical>
      <isbn>0933-7407</isbn>
      <accession-num>ISI:001467704200001</accession-num>
      <number>4</number>
      <electronic-resource-num>10.1111/myc.70058</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010093434</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/2025-05/010093434.pdf</url>
        </pdf-urls>
      </urls>
      <volume>68</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Background: Pulmonary aspergillosis is a major global health concern, yet its diagnosis remains challenging. Aspergillus-specific IgG measurement is essential for identifying chronic and allergic forms. Objective: This study aimed to evaluate a quantitative method, the ImmunoCAP assay IgG m3 (ICAP) (Phadia-ThermoFisher Scientific, Waltham, USA), a qualitative method, the Aspergillus IgG Western blot kit (Asp-WB) (LDBio Diagnostics, Lyon, France) and a combination of both methods for the diagnosis of Aspergillus lung disease. Methods: A retrospective study was conducted at the University Hospital of Marseille, France, during 1 year. Patients undergoing Aspergillus serology were divided into three groups: Group 1 (G1) with ICAP &gt;= 40 mgA/L and positive Asp-WB, Group 2 (G2) with ICAP &gt;= 40 mgA/L and negative Asp-WB and Group 3 (G3) with ICAP &lt; 40 mgA/L and positive Asp-WB. Data were collected on demographics, underlying diseases, imaging and biological outcomes. Patients were classified according to their Aspergillus lung disease, whether acute pulmonary aspergillosis, chronic pulmonary aspergillosis (CPA), allergic broncho-pulmonary aspergillosis (ABPA), colonisation or Aspergillus sensitisation. Results: A total of 536 patients were studied: 173 in G1, 204 in G2 and 200 in G3, with 38 patients found in several groups. The primary underlying disease was cystic fibrosis in 44.6% of patients. Twenty-two patients were diagnosed with ABPA. The number of diagnosed ABPA cases in G1 (20; 11.6%) combining positive ICAP and Asp-WB was significantly higher than that found in the groups with a single positive test result (p &lt; 0.001). Fifteen patients were diagnosed with CPA. Isolated positive Western blot (G3) identified five cases of aspergilloma. Significantly fewer Aspergillus lung diseases were diagnosed in isolated positive ICAP G2 (8.8%) than in G1 (53.8%) and G3 (42.5%) (p &lt; 0.001). Conclusions: This study highlights the benefits of combining Asp-WB and ICAP for the diagnosis of Aspergillus lung disease and the relatively high false-positive rate in patients with isolated positive ICAP results.</abstract>
      <custom6>050 ; 084</custom6>
    </record>
  </records>
</xml>
